This post was originally published on this site
Investing.com — HCW Biologics Inc (NASDAQ:HCWB) has been given a boost after the Food and Drug Administration gave the company clearance to proceed with a Phase 1b Clinical Trial for its pancreatic cancer drug.
Called HCW9218, the drug is the company’s lead candidate, which is why HCW’s share price has seen a significant reaction to the news, surging to a high of $7.05 following Wednesday’s close at $2.92.
Hing C. Wong, Founder and CEO of HCW Biologics, said: “The FDA’s clearance to proceed with our first-in-human trial for HCW9218 in pancreatic cancer is an important milestone for HCW Biologics and our efforts to advance the development of potentially groundbreaking immunotherapy candidates for cancer and other age-related diseases.
On Wednesday, the company announced Lisa Giles and Gary Winer as new members of its board.
